These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 17048975)

  • 1. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
    Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration.
    Kearney BP; Ramanathan S; Cheng AK; Ebrahimi R; Shah J
    J Clin Pharmacol; 2005 Aug; 45(8):935-40. PubMed ID: 16027404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
    Kearney BP; Flaherty JF; Shah J
    Clin Pharmacokinet; 2004; 43(9):595-612. PubMed ID: 15217303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
    Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
    Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
    Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir disoproxil fumarate for the treatment of HIV infection.
    Pham PA; Gallant JE
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):459-69. PubMed ID: 16863446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB; Stone EA; Piacenti FJ
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability study of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy male fasted volunteers.
    Lu C; Jia Y; Yang J; Song Y; Liu W; Ding Y; Sun X; Wen A
    Clin Drug Investig; 2012 May; 32(5):333-8. PubMed ID: 22413748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
    Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
    Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects.
    Hu CY; Liu YM; Liu Y; Chen Q; Wang W; Wu K; Dong J; Li J; Jia JY; Lu C; Sun SX; Yu C; Li X
    Clin Ther; 2013 Dec; 35(12):1884-9. PubMed ID: 24148552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
    Adusumilli S
    Drugs Today (Barc); 2009 Sep; 45(9):679-85. PubMed ID: 19956809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
    Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA
    J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
    Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
    Havens PL; Kiser JJ; Stephensen CB; Hazra R; Flynn PM; Wilson CM; Rutledge B; Bethel J; Pan CG; Woodhouse LR; Van Loan MD; Liu N; Lujan-Zilbermann J; Baker A; Kapogiannis BG; Gordon CM; Mulligan K;
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5619-28. PubMed ID: 24002093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
    Droste JA; Kearney BP; Hekster YA; Burger DM
    J Acquir Immune Defic Syndr; 2006 Jan; 41(1):37-43. PubMed ID: 16340471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.
    Yoshino M; Yagura H; Kushida H; Yonemoto H; Bando H; Ogawa Y; Yajima K; Kasai D; Taniguchi T; Watanabe D; Nishida Y; Kuwahara T; Uehira T; Shirasaka T
    J Infect Chemother; 2012 Apr; 18(2):169-74. PubMed ID: 21968965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.